GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index; 1 of the 23 sources its claims cite were checked for support.
Abstract
Background: Obesity is related to the loss of skeletal muscle mass and function (sarcopenia). The co-existence of obesity and sarcopenia is called sarcopenic obesity (SO). Glucagon like peptide-1 receptor agonists (GLP-1RA) are widely used in the treatment of diabetes and obesity. However, the protective effects of GLP-1RA on skeletal muscle in obesity and SO are not clear. This study investigated the effects of GLP-1RA liraglutide and semaglutide on obesity-induced muscle atrophy and explored the underlying mechanisms. Methods: Thirty-six male C57BL/6J mice were randomly divided into two groups and fed a regular diet and a high-fat diet for 18 weeks, respectively. After establishing an obesity model, mice were further divided into six groups: control group, liraglutide (LIRA) group, semaglutide (SEMA) group, high-fat diet (HFD) group, HFD + LIRA group, HFD + SEMA group, and subcutaneous injection for 4 weeks. The body weight, muscle mass, muscle strength, glycolipid metabolism, muscle atrophy markers, myogenic differentiation markers, GLUT4 and SIRT1 were analyzed. C2C12 myotube cells treated with palmitic acid (PA) were divided into four groups: control group, PA group, PA + LIRA group, PA + SEMA group. The changes in glucose uptake, myotube diameter, lipid droplet infiltration, markers of muscle atrophy, myogenic differentiation markers, GLUT4 and SIRT1 were analyzed, and the changes in related indicators were observed after the addition of SIRT1 inhibitor EX527. Results: Liraglutide and semaglutide reduced HFD-induced body weight gain, excessive lipid accumulation and improved muscle atrophy. Liraglutide and semaglutide eliminated the increase of muscle atrophy markers in skeletal muscle and C2C12 myotubes. Liraglutide and semaglutide restored impaired glucose tolerance and insulin resistance. However, these beneficial effects were attenuated by inhibiting SIRT1 expression. Conclusion: Liraglutide and semaglutide protects skeletal muscle against obesity-induced muscle atrophy via the SIRT1 pathway.
Overview
CoChat Summary
TL;DR
Liraglutide and semaglutide improved obesity-induced skeletal muscle atrophy, lipid accumulation, and insulin resistance in high-fat-diet mice and palmitic-acid-treated C2C12 myotubes. The protective effects were attenuated by SIRT1 inhibition, supporting a SIRT1-dependent mechanism.
Key findings
- In HFD-fed mice, liraglutide and semaglutide reduced body weight gain; the Discussion reports HFD mice lost 17.8% of body weight with liraglutide and 20.1% with semaglutide.
- GLP-1RA treatment improved muscle strength and mass: HFD decreased relative grip strength and limb suspension time, increased body fat/visceral fat, and reduced lean body mass percentage and relative lower-limb muscle weight; liraglutide and semaglutide reversed these changes.
- Liraglutide and semaglutide improved glucose tolerance, insulin resistance, and dyslipidemia, and reduced muscle atrophy markers while increasing myogenic markers, GLUT4, and SIRT1 in HFD mice.
- In PA-treated C2C12 myotubes, liraglutide and semaglutide reduced Atrogin-1/MuRF-1, increased MyoD/Myogenin, improved myotube diameter, lipid accumulation, and 2-NBDG glucose uptake; the SIRT1 inhibitor EX-527 attenuated these improvements.
Methods
- Thirty-six male C57BL/6J mice (8 weeks old, 20.1±1.1 g) were fed a normal diet or HFD (60 kcal% fat) for 18 weeks, then divided into Control, LIRA, SEMA, HFD, HFD+LIRA, and HFD+SEMA groups; liraglutide (400 µg/kg/d) or semaglutide (60 µg/kg/d) was injected subcutaneously for 4 weeks.
- C2C12 myotubes were differentiated and treated with 1.0 mM palmitic acid (PA) for 24 hours, divided into control, PA, PA+LIRA (400 nM), and PA+SEMA (60 nM) groups; EX-527 (100 µM) was used to inhibit SIRT1.
- Outcomes included body weight, muscle mass/strength, IPGTT/ITT, biochemical indices, Micro CT, H&E and Oil Red O staining, qRT-PCR, Western blotting, immunofluorescence, and 2-NBDG glucose uptake; statistics used SPSS 23.0 with mean±SD, t-test/ANOVA, and P<0.05 significance.
Limitations
- The paper does not state a limitations section.
- Evident from the text: findings are preclinical only, using male C57BL/6J mice and C2C12 myotubes, with no human or female data.
- Evident from the text: SIRT1 causal evidence relies mainly on the inhibitor EX-527 in vitro, with no in vivo SIRT1 manipulation; the paper also reports HFD body weight excess as 40% in Results but 49% in Discussion.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
1 Valid · 0 Not valid · 16 Not checked · 72 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“liraglutide and semaglutide treatment significantly relieved the inhibition of SIRT1 in PA treated cells (Figure 5A).”
§ GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway > Results > Liraglutide and Semaglutide Mitigated PA Induced Myotube Atrophy and Insulin Resistance via the SIRT1 Pathway
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“liraglutide and semaglutide treatment eliminated the reduction of SIRT1 signaling pathway induced by HFD (Figure 3G and H).”
§ GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway > Results > Liraglutide and Semaglutide Improved Muscle Atrophy and Insulin Resistance in HFD Mice Through the SIRT1 Pathway
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“indicating severe obesity”
§ GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway > Discussion
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
22 references still to check
A free account verifies the references that are still open.
- Not yet classified. 82
- It may state two separate claims as one. 2
- The quote only partly states this claim. 1
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Risk factors for greater lean tissue loss likely include advanced age, rapid or large absolute weight loss, low dietary protein intake, sedentary lifestyle, and comorbid conditions such as chronic kidney disease or long-standing diabetes [15].”
From Muscle loss and GLP-1R agonists use (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, preclinical data suggest that GLP-1 receptor agonists not only mitigate weight gain but also attenuate muscular atrophy and improve mitochondrial function in skeletal muscle, potentially disrupting the vicious cycle linking adiposity and sarcopenia [56].”
From A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass (2026) · cites this paper as [56]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These effects appear to be mediated, at least in part, by reductions in systemic and local low-grade inflammation and improvements in metabolic and mitochondrial efficiency [56,57,58].”
From A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass (2026) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It is important to emphasize that these findings are very limited and presented in animal and in vitro models.”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“Both liraglutide and semaglutide have been shown to reduce obesity-induced muscle atrophy via a GLP-1/Sirtuin (SIRT1) pathway in rodents (40).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [40]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway > Results > Beneficial Effects of Liraglutide and Semaglutide on Body Weight, Muscle Strength, and Muscle Mass in HFD Mice
“after 18 weeks of feeding, the average body weight of the HFD group was 40% higher than that of the normal diet group”
§ GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway > Discussion
“after 18 weeks, the weight of the HFD group exceeded that of the control group by 49%, indicating severe obesity”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway > Materials and Methods > Animals and Groups
“Liraglutide (400ug/kg/d) and semaglutide (60ug/kg/d) was daily subcutaneous injection for 4 weeks.”
§ GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway > Discussion
“We observed that after subcutaneous injection of liraglutide and semaglutide, the appetite of mice was suppressed. Four months later, mice fed with HFD lost 17.8% of their weight when using liraglutide, and 20.1% of their weight when using semaglutide.”
Citations
Cites
Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,225
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012 · cited 1×
“Atrogin-1 plays a key role in muscle atrophy as muscle specific ubiquitin ligase.(48) Muscle derived regulatory factor Myogenin is crucial for promoting muscle recovery.”
BackgroundTriglyceride accumulation protects against fatty acid-induced lipotoxicity
Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Ory, D. S., & Schaffer, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630588100 · Cited by 2,075
Skeletal muscle: A brief review of structure and function
Frontera, W. R., & Ochala, J. (2015) · Calcified Tissue International · doi:10.1007/s00223-014-9915-y · Cited by 1,758
Mechanisms regulating skeletal muscle growth and atrophy
Schiaffino, S., Dyar, K. A., Ciciliot, S., Blaauw, B., & Sandri, M. (2013) · The FEBS Journal · doi:10.1111/febs.12253 · Cited by 1,492
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382 · cited 1×
“restriction and physical activity.(7) However, there are still some limitations in the treatment of SO.”
BackgroundSIRT1 Functionally Interacts with the Metabolic Regulator and Transcriptional Coactivator PGC-1α
Nemoto, S., Fergusson, M. M., & Finkel, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501485200 · Cited by 1,047
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021 · cited 1×
“There are six GLP-1RA approved for glucose reduction, but only liraglutide and semaglutide are approved for weight loss treatment in the United States at present.(30) The mechanism of liraglutide and semaglutide on weight loss in obese patients is mainly to inhibit appetite and reduce energy intake.”
BackgroundDefinition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., et al. (2022) · Obesity Facts · doi:10.1159/000521241 · Cited by 1,019
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Cited by
Items 101–101 of 101
Metadata
- Authors
- Xiang, J., Qin, L., Zhong, J., Xia, N., & Liang, Y.
- Affiliations
- First Affiliated Hospital of GuangXi Medical University (CN)
- Guangxi Medical University (CN)
- Corresponding author
- Liang, Yuzhen
- Venue
- Diabetes, Metabolic Syndrome and Obesity
- Publisher
- Informa UK Limited
- Published
- 2023-08
- Volume
- Volume 16
- Pages
- 2433-2446
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC10439806
- OpenAlex
- W4385840652
- Cited by
- 100
- References
- 59
- Citations by year
- 2026: 30 · 2025: 47 · 2024: 22 · 2023: 1
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- National Natural Science Foundation of China (8176030057)
- Natural Science Foundation of Guangxi Province
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- liraglutide, semaglutide, GLP-1 receptor agonists, sarcopenic obesity, skeletal muscle atrophy, SIRT1, high-fat diet, insulin resistance, glucose tolerance, GLUT4, palmitic acid, C2C12 myotubes, EX527
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.